Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 5/20 | 0.33 |
| ▸ | KCNK9 | Q9NPC2 | 5/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GPR6 | P46095 | 1/20 | 0.31 |
| ▸ | SMURF2 | Q9HAU4 | 1/20 | 0.31 |
| ▸ | SMURF1 | Q9HCE7 | 1/20 | 0.31 |
| ▸ | USP19 | O94966 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630611 | 0.91 | KDM4E (0.41) | HCAR2ADORA2ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL30509860 | 0.83 | ADORA2A (0.45) | ADORA2ANTRK1KCNK3KCNK9GPR6 | |
| SCHEMBL17843215 | 0.79 | NPSR1 (0.39) | NTRK1SMN1; SMN2GPR6L3MBTL1 | |
| SCHEMBL23353985 | 0.78 | ADORA2A (0.31) | HCAR2ADORA2AKDM4E | |
| SCHEMBL766173 | 0.77 | GPR119 (0.47) | MAPTSMN1; SMN2KDM4EKMT2A | |
| SCHEMBL28976605 | 0.75 | NTRK1 (0.38) | NTRK1KCNK3KCNK9ALDH1A1KDM4E | |
| SCHEMBL30359106 | 0.72 | KCNK3 (0.43) | NTRK1KCNK3KCNK9USP19 | |
| SCHEMBL630753 | 0.72 | CNR2 (0.37) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL8548428 | 0.70 | ALDH1A1 (0.38) | MAPTSMN1; SMN2ALDH1A1KDM4EHTT | |
| SCHEMBL31043803 | 0.69 | HCAR2 (0.33) | HCAR2MAPTSMN1; SMN2KDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755963-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | claimed |
| US-9260408-B2 | Dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-02-16 | — | — | US | claimed |
| EP-2755963-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-23 | — | — | EP | claimed |
| CN-103814021-A | New dihydroquinoline-2-one derivatives | HOFFMANN LA ROCHE | 2014-05-21 | — | — | CN | claimed |
| WO-2013037779-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | claimed |
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CINCOR PHARMA, INC. | 2013-03-21 | — | — | US | claimed |
| EP-1899296-B1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2010-11-17 | — | — | EP | claimed |
| US-7812040-B2 | such as 3-(3-Acetyl-phenyl)-1-[3-(3-chloro-4-pyrrolidin-1-ylmethyl-phenoxy)-cyclobutylmethyl]-1-methyl-urea, used for the treatment of , schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, hypotension, allergies, cardiovascular, gastrointestinal and psychological disorders | PFIZER INC. (US) | 2010-10-12 | — | — | US | claimed |
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2009-05-21 | — | — | US | claimed |
| US-20250154175-A1 | DIAZABICYCLIC SUBSTITUTED IMIDAZOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF BREATHING DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-05-15 | — | — | US | disclosed |
| EP-3653618-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-01-08 | — | — | EP | disclosed |
| US-12180227-B2 | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | BAYER AKTIENGESELLSCHAFT (DE) | 2024-12-31 | — | — | US | disclosed |
| CN-115554300-B | Diazabicyclo-substituted imidazopyrimidines and their use for the treatment of respiratory disorders | 拜耳股份公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-115583959-B | Diazabicyclo-substituted imidazopyrimidines and their use for the treatment of respiratory disorders | 拜耳股份公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-12 | — | — | US | disclosed |
| EP-1899296-B1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2010-11-17 | — | — | EP | disclosed |
| US-7812040-B2 | such as 3-(3-Acetyl-phenyl)-1-[3-(3-chloro-4-pyrrolidin-1-ylmethyl-phenoxy)-cyclobutylmethyl]-1-methyl-urea, used for the treatment of , schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, hypotension, allergies, cardiovascular, gastrointestinal and psychological disorders | PFIZER INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2009-05-21 | — | — | US | disclosed |
| EP-1899296-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006136924-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | HRH3, HRH4, HRH2 | HCAR2 72/4885ADORA2A 251/4885NTRK1 642/4885 |
| US-12180227-B2 | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | HIF1AN, QDPR, DHPS | HCAR2 1049/4885ADORA2A 179/4885NTRK1 3674/4885 |
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | TAAR1, HCRTR1, NPY1R | HCAR2 380/4885ADORA2A 72/4885NTRK1 729/4885 |
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CYP11B1, CYP11B2, HSD11B1 | HCAR2 906/4885ADORA2A 794/4885NTRK1 4459/4885 |
| US-20250154175-A1 | DIAZABICYCLIC SUBSTITUTED IMIDAZOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF BREATHING DISORDERS | HIF1AN, QDPR, HNMT | HCAR2 814/4885ADORA2A 108/4885NTRK1 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.